Breaking Finance News

Credit Suisse Group AG downgraded Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to Neutral in a report released today.

Yesterday Taro Pharmaceutical Industries Ltd. (NYSE:TARO) traded 0.61% higher at $107.34. The company’s 50-day moving average is $106.86 and its 200-day moving average is $111.44. The last stock close price is down 2.48% from the 200-day moving average, compared to the S&P 500 which has increased 0.01% over the same time. 31,995 shares of the stock were exchanged, down from an average trading volume of 103,374

Credit Suisse Group AG has downgraded Taro Pharmaceutical Industries Ltd. (NYSE:TARO) to Neutral in a report released on 5/23/2017.

See Chart Below

Taro Pharmaceutical Industries Ltd. (NYSE:TARO)

Taro Pharmaceutical Industries Ltd. has a 52 week low of $92.28 and a 52 week high of $124.52 with a P/E ratio of 11.63 The company’s market cap is currently $0.

General Information About Taro Pharmaceutical Industries Ltd. (NYSE:TARO)

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *